Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 2/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP12 | P39900 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445917 | 0.92 | HPGD (0.58) | BCL2MCL1PARP10SRD5A2NPY5R | |
| SCHEMBL6981600 | 0.85 | PARP10 (0.55) | BCL2MCL1PARP10SRD5A2NPY5R | |
| SCHEMBL11433567 | 0.85 | PARP10 (0.55) | BCL2MCL1PARP10SRD5A2NPY5R | |
| SCHEMBL11691009 | 0.85 | PARP10 (0.55) | BCL2MCL1PARP10SRD5A2NPY5R | |
| SCHEMBL13203385 | 0.85 | HPGD (0.73) | BCL2MCL1PARP10ALDH1A1RAB9A | |
| SCHEMBL13687470 | 0.85 | PARP10 (0.58) | BCL2MCL1PARP10ALDH1A1RAB9A | |
| SCHEMBL22548771 | 0.85 | PARP10 (0.61) | PARP10ALDH1A1RAB9AMAPTHPGD | |
| Hydrochloric Acid SCHEMBL9642871 | 0.84 | PARP10 (0.58) | BCL2MCL1PARP10SRD5A2NPY5R | |
| SCHEMBL13689271 | 0.84 | AKR1C3 (0.66) | BCL2MCL1PARP10ALDH1A1RAB9A | |
| SCHEMBL13687458 | 0.83 | BCL2 (0.53) | BCL2MCL1PARP10RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4065503-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-12-27 | — | — | US | claimed |
| US-10947271-B2 | Antibacterial agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-16 | — | — | US | disclosed |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-20 | — | — | US | disclosed |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-20 | — | — | US | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110201794-A1 | Disaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2011-08-18 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1652833-A1 | PROCESS FOR PRODUCING 4-HYDROXYDIPHENYL ETHER | Sumitomo Chemical Company, Limited (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-4175138-A | α-Alkyl-p-phenoxy benzyl alcohols, compositions and treating lipidemia | SANDOZ, INC. (US) | 1979-11-20 | — | — | US | disclosed |
| US-4137313-A | ANTICOAGULANTS, ANTIPHLOGISTIC AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-01-30 | — | — | US | disclosed |
| US-4085149-A | HYPOLIPIDEMIC | SANDOZ, INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4065503-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-3962459-A | Lipidemia treatment with p-phenoxy-alkylphenone compositions | SANDOZ, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201794-A1 | Disaccharides for drug discovery | UGCG, STT3A, DDOST | BCL2 4702/4885MCL1 2128/4885PARP10 3302/4885 |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | VNN1, ASNS, AAAS | BCL2 2614/4885MCL1 1243/4885PARP10 3073/4885 |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | BCL2 1133/4885MCL1 1001/4885PARP10 2364/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | BCL2 1324/4885MCL1 975/4885PARP10 1747/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | BCL2 1324/4885MCL1 975/4885PARP10 1747/4885 |
| US-10947271-B2 | Antibacterial agents | VNN1, ASNS, AAAS | BCL2 2614/4885MCL1 1243/4885PARP10 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.